Please login to the form below

Not currently logged in
Email:
Password:

Genzyme’s Henk Doude van Troostwijk joins Raptor Pharmaceutical

US pharma company will also set up European headquarters in the Netherlands

Raptor Pharmaceutical has appointed Henk Doude van Troostwijk as general manager of European commercial operations.

He will be responsible for building and managing Raptor's presence in Europe following the California-based company's decision to establish European headquarters in Leiden, the Netherlands.

Doude van Troostwijk will join the company on April 15 from Sanofi's Genzyme business, where he most recently served as business unit director, oncology, for haematology and transplantation in Northern Europe.

Prior to that he held various roles at Bioenvision, MSD, Bristol-Myers Squibb and Nycomed.

At Raptor his initial focus will be on preparing for the launch and marketing of the company's RP103, an orphan treatment for cell toxicity condition nephropathic cystinosis that is currently being considered for approval by European regulatory authorities.

Patrick Reichenberger, vice president of commercial operations, said: "We are very excited to have Henk join our team to lead the commercial operations in Europe.

“His expertise in gaining market access, working with orphan products and leading commercial teams will be critical as we prepare for the potential launch of RP103 in Europe."

2nd April 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Novasecta

We are a specialist strategy consulting firm for pharmaceutical and biotech companies. We help our clients to achieve significant performance...

Latest intelligence

Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...

Infographics